{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:27:33Z","timestamp":1791908853855,"version":"4.3.4"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Biomarkers offer potential alternatives to endoscopies in monitoring ulcerative colitis (UC) progression and therapeutic response. This post hoc analysis of the ELEVATE UC clinical program assessed potential predictive values of fecal calprotectin (fCAL) and high-sensitivity C-reactive protein (hsCRP) as biomarkers and associated responses to etrasimod, an oral, once-daily, selective sphingosine 1-phosphate (S1P)1,4,5 receptor modulator for the treatment of moderately to severely active UC, in 2 phase 3 clinical trials.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In ELEVATE UC 52 and ELEVATE UC 12, patients were randomized 2:1 to 2 mg of etrasimod once daily or placebo for 52 or 12 weeks, respectively. Fecal calprotectin\/hsCRP differences between responders and nonresponders for efficacy end points (clinical remission, clinical response, endoscopic improvement-histologic remission [EIHR]) were assessed by Wilcoxon P-values. Sensitivity and specificity were presented as receiver operating characteristics (ROC) curves with area under the curve (AUC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In ELEVATE UC 52 and ELEVATE UC 12, 289 and 238 patients received etrasimod and 144 and 116 received placebo, respectively. Baseline fCAL\/hsCRP concentrations were generally balanced. Both trials had lower week-12 median fCAL levels in week-12 responders vs nonresponders receiving etrasimod for clinical remission, clinical response, and EIHR (all P\u2005&amp;lt;\u2005.001), with similar trends for hsCRP levels (all P\u2005&amp;lt;\u2005.01). For etrasimod, AUCs for fCAL\/hsCRP and EIHR were 0.85\/0.74 (week 12; ELEVATE UC 52), 0.83\/0.69 (week 52; ELEVATE UC 52), and 0.80\/0.65 (week 12; ELEVATE UC 12).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Fecal calprotectin\/hsCRP levels decreased with etrasimod treatment; ROC analyses indicated a prognostic correlation between fCAL changes during induction and short-\/long-term treatment response.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izae111","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T12:11:41Z","timestamp":1718885501000},"page":"923-934","source":"Crossref","is-referenced-by-count":2,"title":["The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-898X","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"first","affiliation":[{"name":"Department of Medicine and Department of Epidemiology and Biostatistics, Western University , London, Ontario ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T","family":"Rubin","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine Inflammatory Bowel Disease Center , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3898-7093","authenticated-orcid":false,"given":"Bram","family":"Verstockt","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven , Leuven,","place":["Belgium"]},{"name":"Department of Chronic Diseases and Metabolism, Translational Research in Gastrointestinal Disorders, KU Leuven , Leuven ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayhan H","family":"\u00c7ekin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, University of Health Sciences, Antalya Training and Research Hospital , Antalya ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-0574","authenticated-orcid":false,"given":"Maria T","family":"Abreu","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Crohn\u2019s and Colitis Center, University of Miami Miller School of Medicine , Miami, FL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlie W","family":"Lees","sequence":"additional","affiliation":[{"name":"The Edinburgh Inflammatory Bowel Disease Unit, Western General Hospital , Edinburgh, Scotland ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0064-698X","authenticated-orcid":false,"given":"Marc","family":"Fellmann","sequence":"additional","affiliation":[{"name":"Pfizer AG , Z\u00fcrich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C","family":"Woolcott","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Collegeville, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Crosby","sequence":"additional","affiliation":[{"name":"Pfizer Inc , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Wu","sequence":"additional","affiliation":[{"name":"Pfizer Inc , Cambridge, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Bhattacharjee","sequence":"additional","affiliation":[{"name":"Pfizer Healthcare India Pvt Ltd , Chennai, Tamil Nadu ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Herman","sequence":"additional","affiliation":[{"name":"Pfizer Inc , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guibao","family":"Gu","sequence":"additional","affiliation":[{"name":"Pfizer Inc , La Jolla, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0055-958X","authenticated-orcid":false,"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[{"name":"Medizinische Klinik f\u00fcr Gastroenterologie, Infektiologie und Rheumatologie, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin, corporate member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin , Berlin ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"issue":"10080","key":"2025041105240547500_CIT0001","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet."},{"issue":"6","key":"2025041105240547500_CIT0002","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1093\/ecco-jcc\/jjx008","article-title":"Third European evidence-based consensus on diagnosis and management of ulcerative colitis. part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders","volume":"11","author":"Magro","year":"2017","journal-title":"J Crohns Colitis."},{"issue":"5","key":"2025041105240547500_CIT0003","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"3","key":"2025041105240547500_CIT0004","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1053\/j.gastro.2022.12.007","article-title":"AGA clinical practice guideline on the role of biomarkers for the management of ulcerative colitis","volume":"164","author":"Singh","year":"2023","journal-title":"Gastroenterology."},{"issue":"1","key":"2025041105240547500_CIT0005","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1053\/j.gastro.2015.09.001","article-title":"Correlation between concentrations of fecal calprotectin and outcomes of patients with ulcerative colitis in a phase 2 trial","volume":"150","author":"Sandborn","year":"2016","journal-title":"Gastroenterology."},{"issue":"3","key":"2025041105240547500_CIT0006","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3164\/jcbn.18-92","article-title":"Capabilities of fecal calprotectin and blood biomarkers as surrogate endoscopic markers according to ulcerative colitis disease type","volume":"64","author":"Sonoyama","year":"2019","journal-title":"J Clin Biochem Nutr."},{"issue":"8","key":"2025041105240547500_CIT0007","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"issue":"7","key":"2025041105240547500_CIT0008","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","article-title":"Long-term efficacy and safety of ozanimod in moderately to severely active ulcerative colitis: results from the open-label extension of the randomized, phase 2 TOUCHSTONE study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J Crohns Colitis."},{"issue":"3","key":"2025041105240547500_CIT0009","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/gut.2004.043406","article-title":"Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn\u2019s disease","volume":"54","author":"Costa","year":"2005","journal-title":"Gut."},{"issue":"3","key":"2025041105240547500_CIT0010","first-page":"77","article-title":"Faecal calprotectin","volume":"39","author":"Pathirana","year":"2018","journal-title":"Clin Biochem Rev"},{"key":"2025041105240547500_CIT0011","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/1471-2474-15-368","article-title":"How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis","volume":"15","author":"Siemons","year":"2014","journal-title":"BMC Musculoskelet Disord."},{"key":"2025041105240547500_CIT0012","doi-asserted-by":"publisher","first-page":"39940","DOI":"10.1038\/srep39940","article-title":"Body mass index moderates the relationship between C-reactive protein and depressive symptoms: evidence from the China Health and Retirement Longitudinal Study","volume":"7","author":"Qin","year":"2017","journal-title":"Sci Rep."},{"issue":"10383","key":"2025041105240547500_CIT0013","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): 2 randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet."},{"issue":"5","key":"2025041105240547500_CIT0014","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun Rev."},{"issue":"4","key":"2025041105240547500_CIT0015","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","article-title":"Modulation of sphingosine-1-phosphate in ulcerative colitis","volume":"20","author":"Argollo","year":"2020","journal-title":"Expert Opin Biol Ther."},{"issue":"5","key":"2025041105240547500_CIT0016","doi-asserted-by":"publisher","first-page":"e12836","DOI":"10.1111\/cmi.12836","article-title":"Sphingosine-1-phosphate receptors and innate immunity","volume":"20","author":"Bryan","year":"2018","journal-title":"Cell Microbiol."},{"issue":"1","key":"2025041105240547500_CIT0017","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1&lt;32::aid-cncr2820030106&gt;3.0.co;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer."},{"key":"2025041105240547500_CIT0018","author":"US Food and Drug Administration"},{"key":"2025041105240547500_CIT0019","volume-title":"Ulcerative Colitis: Clinical Trial Endpoints: Guidance for Industry","author":"FDA","year":"2016"},{"issue":"2","key":"2025041105240547500_CIT0020","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1053\/gast.2002.34755","article-title":"Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease","volume":"123","author":"Tibble","year":"2002","journal-title":"Gastroenterology."},{"key":"2025041105240547500_CIT0021","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2147\/CEG.S51902","article-title":"Fecal calprotectin in inflammatory bowel disease","volume":"9","author":"Walsham","year":"2016","journal-title":"Clin Exp Gastroenterol"},{"issue":"2","key":"2025041105240547500_CIT0022","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"14","key":"2025041105240547500_CIT0023","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med."},{"issue":"4","key":"2025041105240547500_CIT0024","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/ecco-jcc\/jjy184","article-title":"Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis\u2013a prospective analysis","volume":"13","author":"Walsh","year":"2019","journal-title":"J Crohns Colitis."},{"issue":"6","key":"2025041105240547500_CIT0025","doi-asserted-by":"publisher","first-page":"885","DOI":"10.14309\/ajg.0000000000000596","article-title":"Incorporating fecal calprotectin into clinical practice for patients with moderate-to-severely active ulcerative colitis treated with biologics or small-molecule inhibitors","volume":"115","author":"Dulai","year":"2020","journal-title":"Am J Gastroenterol."},{"issue":"7-8","key":"2025041105240547500_CIT0026","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.clinbiochem.2011.10.015","article-title":"Ruling out IBD: estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin","volume":"45","author":"Mindemark","year":"2012","journal-title":"Clin Biochem."},{"issue":"1","key":"2025041105240547500_CIT0027","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/imj.14027","article-title":"Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study","volume":"49","author":"Motaganahalli","year":"2019","journal-title":"Intern Med J."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izae111\/58287176\/izae111.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/923\/58287176\/izae111.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/4\/923\/58287176\/izae111.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T05:24:28Z","timestamp":1744349068000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/4\/923\/7696535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,6,20]]},"published-print":{"date-parts":[[2025,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izae111","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,6,20]]}}}